Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites

Cancers

Volumn 8, Issue 10, 2016, Pages

  Tomaić, Vjekoslav ^a,b  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Cancer; E6 and E7 oncoproteins; HPV

Indexed keywords

NOTCH RECEPTOR; PDZ PROTEIN; PROTEASOME; PROTEIN E6; PROTEIN E7; PROTEIN P53; TELOMERASE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CELL CYCLE REGULATION; CENTROSOME; DNA REPLICATION; GENE AMPLIFICATION; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS ALPHA; HUMAN PAPILLOMAVIRUS BETA; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SKIN EPITHELIUM; UTERINE CERVIX CANCER; VIRAL GENETICS; VIROGENESIS; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; WART VIRUS;

EID: 84992665677     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers8100095     Document Type: Review

References (194)

1. Ganti, K.; Broniarczyk, J.; Manoubi,W.; Massimi, P.; Mittal, S.; Pim, D.; Szalmas, A.; Thatte, J.; Thomas, M.; Tomaić, V.; et al. The human papillomavirus E6 PDZ binding motif: From life cycle to malignancy. Viruses 2015, 7, 3530-3551. [CrossRef] [PubMed]
2. Zur Hausen, H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002, 2, 342-350. [CrossRef] [PubMed]
3. Parkin, D.M.; Bray, F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006, 24, 11-25. [CrossRef] [PubMed]
4. Bouvard, V.; Baan, R.; Straif, K.; Grosse, Y.; Secretan, B.; El Ghissassi, F.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; et al. A review of human carcinogens-Part B: Biological agents. Lancet Oncol. 2009, 10, 321-322. [CrossRef]
5. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 90 Human Papillomaviruses; IARC Press: Lyon, France, 2007; Volume 90.
6. Bernard, H.U.; Burk, R.D.; Chen, Z.; van Doorslaer, K.; zur Hausen, H.; de Villiers, E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401, 70-79. [CrossRef] [PubMed]
7. De Villiers, E.M.; Fauquet, C.; Broker, T.R.; Bernard, H.U.; zur Hausen, H. Classification of papillomaviruses. Virology 2004, 324, 17-27. [CrossRef] [PubMed]
8. Thomas, M.; Narayan, N.; Pim, D.; Tomaić, V.; Massimi, P.; Nagasaka, K.; Kranjec, C.; Gammoh, N.; Banks, L. Human papillomaviruses, cervical cancer and cell polarity. Oncogene 2008, 27, 7018-7030. [CrossRef] [PubMed]
9. Chaturvedi, A.K.; Anderson, W.F.; Lortet-Tieulent, J.; Curado, M.P.; Ferlay, J.; Franceschi, S.; Rosenberg, P.S.; Bray, F.; Gillison, M.L. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J. Clin. Oncol. 2013, 31, 4550-4559. [CrossRef] [PubMed]
10. Combes, J.D.; Chen, A.A.; Franceschi, S. Prevalence of human papillomavirus in cancer of the oropharynx by gender. Cancer Epidemiol. Biomark. Prev. 2014, 23, 2954-2958. [CrossRef] [PubMed]
11. Howley, P.M.; Pfister, H.J. Beta genus papillomaviruses and skin cancer. Virology 2015, 479, 290-296. [CrossRef] [PubMed]
12. Orth, G. Epidermodysplasia verruciformis: A model for understanding the oncogenicity of human papillomaviruses. Ciba Found. Symp. 1986, 120, 157-174. [PubMed]
13. Quint, K.D.; Genders, R.E.; de Koning, M.N.; Borgogna, C.; Gariglio, M.; Bouwes Bavinck, J.N.; Doorbar, J.; Feltkamp, M.C. Human Beta-papillomavirus infection and keratinocyte carcinomas. J. Pathol. 2015, 235, 342-354. [CrossRef] [PubMed]
14. Doorbar, J. Model systems of human papillomavirus-associated disease. J. Pathol. 2016, 238, 166-179. [CrossRef] [PubMed]
15. Jackson, S.; Storey, A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000, 19, 592-598. [CrossRef] [PubMed]
16. Wallace, N.A.; Robinson, K.; Howie, H.L.; Galloway, D.A. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLoS Pathog. 2012, 8, e1002807. [CrossRef] [PubMed]
17. Meyers, J.M.; Munger, K. The viral etiology of skin cancer. J. Investig. Dermatol. 2014, 34, E29-E32. [CrossRef] [PubMed]
18. Doorbar, J.; Quint, W.; Banks, L.; Bravo, I.G.; Stoler, M.; Broker, T.R.; Stanley, M.A. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30, F55-F70. [CrossRef] [PubMed]
19. Meyers, C.; Laimins, L.A. In vitro systems for the study and propagation of human papillomaviruses. Curr. Top. Microbiol. Immunol. 1994, 186, 199-215. [PubMed]
20. Chow, L.T. Model systems to study the life cycle of human papillomaviruses and HPV-associated cancers. Virol. Sin. 2015, 30, 92-100. [CrossRef] [PubMed]
21. Allen-Hoffmann, B.L.; Schlosser, S.J.; Ivarie, C.A.; Sattler, C.A.; Meisner, L.F.; O’Connor, S.L. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J. Investig. Dermatol. 2000, 114, 444-455. [CrossRef] [PubMed]
22. Fang, L.; Meyers, C.; Budgeon, L.R.; Howett, M.K. Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. Virology 2006, 347, 28-35. [CrossRef] [PubMed]
23. Griffin, H.; Wu, Z.; Marnane, R.; Dewar, V.; Molijn, A.; Quint, W.; van Hoof, C.; Struyf, F.; Colau, B.; Jenkins, D.; et al. E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. PLoS ONE 2012, 7, e49974. [CrossRef] [PubMed]
24. Andrews, E.; Seaman,W.T.;Webster-Cyriaque, J. Oropharyngeal carcinoma in non-smokers and non-drinkers: A role for HPV. Oral Oncol. 2009, 45, 486-491. [CrossRef] [PubMed]
25. Doorbar, J.; Egawa, N.; Griffin, H.; Kranjec, C.; Murakami, I. Human papillomavirus molecular biology and disease association. Rev. Med. Virol. 2015, 25, 2-23. [CrossRef] [PubMed]
26. Fehrmann, F.; Laimins, L.A. Human papillomaviruses: Targeting differentiating epithelial cells for malignant transformation. Oncogene 2003, 22, 5201-5207. [CrossRef] [PubMed]
27. Genther, S.M.; Sterling, S.; Duensing, S.; Münger, K.; Sattler, C.; Lambert, P.F. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J. Virol. 2003, 77, 2832-2842. [CrossRef] [PubMed]
28. Galloway, D.A.; Laimins, L.A. Human papillomaviruses: Shared and distinct pathways for pathogenesis. Curr. Opin. Virol. 2015, 14, 87-92. [CrossRef] [PubMed]
29. Lazarczyk, M.; Pons, C.; Mendoza, J.A.; Cassonnet, P.; Jacob, Y.; Favre, M. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J. Exp. Med. 2008, 205, 35-42. [CrossRef] [PubMed]
30. Lazarczyk, M.; Cassonnet, P.; Pons, C.; Jacob, Y.; Favre, M. The EVER proteins as a natural barrier against papillomaviruses: A new insight into the pathogenesis of human papillomavirus infections. Microbiol. Mol. Biol. Rev. 2009, 73, 348-370. [CrossRef] [PubMed]
31. Androphy, E.J.; Hubbert, N.L.; Schiller, J.T.; Lowy, D.R. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J. 1987, 6, 989-992. [PubMed]
32. Smotkin, D.; Wettstein, F.O. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc. Natl. Acad. Sci. USA 1986, 83, 4680-4684. [CrossRef] [PubMed]
33. Gao, G.; Johnson, S.H.; Kasperbauer, J.L.; Eckloff, B.W.; Tombers, N.M.; Vasmatzis, G.; Smith, D.I. Mate pair sequencing of oropharyngeal squamous cell carcinomas reveals that HPV integration occurs much less frequently than in cervical cancer. J. Clin. Virol. 2014, 59, 195-200. [CrossRef] [PubMed]
34. Alvarez-Salas, L.M.; Cullinan, A.E.; Siwkowski, A.; Hampel, A.; DiPaolo, J.A. Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc. Natl. Acad. Sci. USA 1998, 95, 1189-1194. [CrossRef] [PubMed]
35. Butz, K.; Denk, C.; Ullmann, A.; Scheffner, M.; Hoppe-Seyler, F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. USA 2000, 97, 6693-6697. [CrossRef] [PubMed]
36. Butz, K.; Ristriani, T.; Hengstermann, A.; Denk, C.; Scheffner, M.; Hoppe-Seyler, F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003, 22, 5938-5945. [CrossRef] [PubMed]
37. Steele, C.; Sacks, P.G.; Adler-Storthz, K.; Shillitoe, E.J. Effect on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18. Cancer Res. 1992, 52, 4706-4711. [PubMed]
38. Von Knebel Doeberitz, M.; Rittmüller, C.; zur Hausen, H.; Dürst, M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int. J. Cancer. 1992, 51, 831-834. [CrossRef] [PubMed]
39. Yoshinouchi, M.; Yamada, T.; Kizaki, M.; Fen, J.; Koseki, T.; Ikeda, Y.; Nishihara, T.; Yamato, K. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol. Ther. 2003, 8, 762-768. [CrossRef] [PubMed]
40. Barbosa, M.S.; Schlegel, R. The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989, 4, 1529-1532. [PubMed]
41. Hawley-Nelson, P.; Vousden, K.H.; Hubbert, N.L.; Lowy, D.R.; Schiller, J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989, 8, 3905-3910. [PubMed]
42. Mantovani, F.; Banks, L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001, 20, 7874-7887. [CrossRef] [PubMed]
43. Riley, R.R.; Duensing, S.; Brake, T.; Münger, K.; Lambert, P.F.; Arbeit, J.M. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 2003, 63, 4862-4871. [PubMed]
44. Strati, K.; Lambert, P.F. Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res. 2007, 67, 11585-11593. [CrossRef] [PubMed]
45. Pim, D.; Bergant, M.; Boon, S.S.; Ganti, K.; Kranjec, C.; Massimi, P.; Subbaiah, V.K.; Thomas, M.; Tomaić, V.; Banks, L. Human papillomaviruses and the specificity of PDZ domain targeting. FEBS J. 2012, 279, 3530-3537. [CrossRef] [PubMed]
46. Barbosa, M.S.; Wettstein, F.O. Transcription of the cottontail rabbit papillomavirus early region and identification of two E6 polypeptides in COS-7 cells. J. Virol. 1987, 61, 2938-2942. [PubMed]
47. Cole, S.T.; Danos, O. Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J. Mol. Biol. 1987, 193, 599-608. [CrossRef]
48. Kanda, T.; Watanabe, S.; Zanma, S.; Sato, H.; Furuno, A.; Yoshiike, K. Human papillomavirus type 16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. Virology 1991, 185, 536-543. [CrossRef]
49. Sherman, L.; Schlegel, R. Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. J. Virol. 1996, 70, 3269-3279. [PubMed]
50. Nominé, Y.; Masson, M.; Charbonnier, S.; Zanier, K.; Ristriani, T.; Deryckère, F.; Sibler, A.P.; Desplancq, D.; Atkinson, R.A.;Weiss, E.; et al. Structural and functional analysis of E6 oncoprotein: Insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol. Cell 2006, 21, 665-678. [CrossRef] [PubMed]
51. Zanier, K.; Ruhlmann, C.; Melin, F.; Masson, M.; Ould M’hamed Ould Sidi, A.; Bernard, X.; Fischer, B.; Brino, L.; Ristriani, T.; Rybin, V.; et al. E6 proteins from diverse papillomaviruses self-associate both in vitro and in vivo. J. Mol. Biol. 2010, 396, 90-104. [CrossRef] [PubMed]
52. Zanier, K.; Charbonnier, S.; Sidi, A.O.; McEwen, A.G.; Ferrario, M.G.; Poussin-Courmontagne, P.; Cura, V.; Brimer, N.; Babah, K.O.; Ansari, T.; et al. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science 2013, 339, 694-698. [CrossRef] [PubMed]
53. Pim, D.; Banks, L. Interaction of viral oncoproteins with cellular target molecules: Infection with high-risk vs low-risk human papillomaviruses. APMIS 2010, 118, 471-493. [CrossRef] [PubMed]
54. Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420, 25-27. [CrossRef]
55. Ashcroft, M.; Vousden, K.H. Regulation of p53 stability. Oncogene 1999, 18, 7637-7643. [CrossRef] [PubMed]
56. Hengstermann, A.; Linares, L.K.; Ciechanover, A.; Whitaker, N.J.; Scheffner, M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc. Natl. Acad. Sci. USA 2001, 98, 1218-1223. [CrossRef] [PubMed]
57. Pim, D.; Storey, A.; Thomas, M.; Massimi, P.; Banks, L. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 1994, 9, 1869-1876. [PubMed]
58. Patel, D.; Huang, S.M.; Baglia, L.A.; McCance, D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 1999, 18, 5061-5072. [CrossRef] [PubMed]
59. Zimmermann, H.; Degenkolbe, R.; Bernard, H.U.; O’Connor, M.J. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 1999, 73, 6209-6219. [PubMed]
60. Thomas, M.C.; Chiang, C.M. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol. Cell 2005, 17, 251-264. [CrossRef] [PubMed]
61. Scheffner, M.; Huibregtse, J.M.; Vierstra, R.D.; Howley, P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75, 495-505. [CrossRef]
62. Huibregtse, J.M.; Scheffner, M.; Howley, P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell. Biol. 1993, 13, 4918-4927. [CrossRef] [PubMed]
63. Huibregtse, J.M.; Scheffner, M.; Howley, P.M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell. Biol. 1993, 13, 775-784. [CrossRef] [PubMed]
64. Talis, A.L.; Huibregtse, J.M.; Howley, P.M. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 1998, 273, 6439-6445. [CrossRef] [PubMed]
65. Tomaić, V.; Pim, D.; Banks, L. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 2009, 393, 7-10. [CrossRef] [PubMed]
66. Tomaić, V.; Pim, D.; Thomas, M.; Massimi, P.; Myers, M.P.; Banks, L. Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD. J. Virol. 2011, 85, 3120-3127. [CrossRef] [PubMed]
67. Vos, R.M.; Altreuter, J.; White, E.A.; Howley, P.M. The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability. J. Virol. 2009, 83, 8885-8892. [CrossRef] [PubMed]
68. Tomaić, V.; Ganti, K.; Pim, D.; Bauer, C.; Blattner, C.; Banks, L. Interaction of HPV E6 oncoproteins with specific proteasomal subunits. Virology 2013, 446, 389-396. [CrossRef] [PubMed]
69. Krajewski, S.; Krajewska, M.; Reed, J.C. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res. 1996, 56, 2849-2855. [PubMed]
70. Jackson, S.; Harwood, C.; Thomas, M.; Banks, L.; Storey, A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev. 2000, 14, 3065-3073. [CrossRef] [PubMed]
71. Thomas, M.; Banks, L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene. 1998, 17, 2943-2954. [CrossRef] [PubMed]
72. Thomas, M.; Banks, L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J. Gen. Virol. 1999, 80, 1513-1517. [CrossRef] [PubMed]
73. Borbély, A.A.; Murvai, M.; Kónya, J.; Beck, Z.; Gergely, L.; Li, F.; Veress, G. Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J. Gen. Virol. 2006, 87, 287-294. [CrossRef] [PubMed]
74. Filippova, M.; Song, H.; Connolly, J.L.; Dermody, T.S.; Duerksen-Hughes, P.J. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 2002, 277, 21730-21739. [CrossRef] [PubMed]
75. Filippova, M.; Parkhurst, L.; Duerksen-Hughes, P.J. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 2004, 279, 25729-25744. [CrossRef] [PubMed]
76. Filippova, M.; Johnson, M.M.; Bautista, M.; Filippov, V.; Fodor, N.; Tungteakkhun, S.S.; Williams, K.; Duerksen-Hughes, P.J. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 2007, 81, 4116-4129. [CrossRef] [PubMed]
77. Shay, J.W.;Wright,W.E. Senescence and immortalization: Role of telomeres and telomerase. Carcinogenesis 2005, 26, 867-874. [CrossRef] [PubMed]
78. Snijders, P.J.; van Duin, M.; Walboomers, J.M.; Steenbergen, R.D.; Risse, E.K.; Helmerhorst, T.J.; Verheijen, R.H.; Meijer, C.J. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: Strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res. 1998, 58, 3812-3818. [PubMed]
79. Klingelhutz, A.J.; Foster, S.A.; McDougall, J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996, 380, 79-82. [CrossRef] [PubMed]
80. Veldman, T.; Horikawa, I.; Barrett, J.C.; Schlegel, R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J. Virol. 2001, 75, 4467-4472. [CrossRef] [PubMed]
81. Gewin, L.; Galloway, D.A. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J. Virol. 2001, 75, 7198-7201. [CrossRef] [PubMed]
82. Veldman, T.; Liu, X.; Yuan, H.; Schlegel, R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. USA 2003, 100, 8211-8216. [CrossRef] [PubMed]
83. Liu, X.; Yuan, H.; Fu, B.; Disbrow, G.L.; Apolinario, T.; Tomaić, V.; Kelley, M.L.; Baker, C.C.; Huibregtse, J.; Schlegel, R. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J. Biol. Chem. 2005, 280, 10807-10816. [CrossRef] [PubMed]
84. Sekaric, P.; Cherry, J.J.; Androphy, E.J. Binding of human papillomavirus type 16 E6 to E6AP is not required for activation of hTERT. J. Virol. 2008, 82, 71-76. [CrossRef] [PubMed]
85. Xu, M.; Luo, W.; Elzi, D.J.; Grandori, C.; Galloway, D.A. NFX1 interacts with mSin3A/histone deacetylase to repress hTERT transcription in keratinocytes. Mol. Cell. Biol. 2008, 28, 4819-4828. [CrossRef] [PubMed]
86. Songyang, Z.; Fanning, A.S.; Fu, C.; Xu, J.; Marfatia, S.M.; Chishti, A.H.; Crompton, A.; Chan, A.C.; Anderson, J.M.; Cantley, L.C. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 1997, 275, 73-77. [CrossRef] [PubMed]
87. Javier, R.T. Cell polarity proteins: Common targets for tumorigenic human viruses. Oncogene 2008, 27, 7031-7046. [CrossRef] [PubMed]
88. Van Ham, M.; Hendriks, W. PDZ domains-glue and guide. Mol. Biol. Rep. 2003, 30, 69-82. [CrossRef] [PubMed]
89. Kiyono, T.; Hiraiwa, A.; Fujita, M.; Hayashi, Y.; Akiyama, T.; Ishibashi, M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc. Natl. Acad. Sci. USA 1997, 94, 11612-11616. [CrossRef] [PubMed]
90. Watson, R.A.; Thomas, M.; Banks, L.; Roberts, S. Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J. Cell Sci. 2003, 116, 4925-4934. [CrossRef] [PubMed]
91. Nguyen, M.L.; Nguyen, M.M.; Lee, D.; Griep, A.E.; Lambert, P.F. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6‘s induction of epithelial hyperplasia in vivo. J. Virol. 2003, 77, 6957-6964. [CrossRef] [PubMed]
92. Delury, C.P.; Marsh, E.K.; James, C.D.; Boon, S.S.; Banks, L.; Knight, G.L.; Roberts, S. The role of protein kinase A regulation of the E6 PDZ-binding domain during the differentiation-dependent life cycle of human papillomavirus type 18. J. Virol. 2013, 87, 9463-9472. [CrossRef] [PubMed]
93. Lee, C.; Laimins, L.A. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J. Virol. 2004, 78, 12366-12377. [CrossRef] [PubMed]
94. Thomas, M.; Myers, M.P.; Massimi, P.; Guarnaccia, C.; Banks, L. Analysis of Multiple HPV E6 PDZ Interactions Defines Type-Specific PDZ Fingerprints That Predict Oncogenic Potential. PLoS Pathog. 2016, 12, e1005789. [CrossRef] [PubMed]
95. Thomas, M.; Glaunsinger, B.; Pim, D.; Javier, R.; Banks, L. HPV E6 and MAGUK protein interactions: Determination of the molecular basis for specific protein recognition and degradation. Oncogene 2001, 20, 5431-5439. [CrossRef] [PubMed]
96. Thomas, M.; Massimi, P.; Navarro, C.; Borg, J.P.; Banks, L. The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene 2005, 24, 6222-6230. [CrossRef] [PubMed]
97. Kranjec, C.; Tomaić, V.; Massimi, P.; Nicolaides, L.; Doorbar, J.; Banks, L. The high-risk HPV E6 target scribble (hScrib) is required for HPV E6 expression in cervical tumour-derived cell lines. Papillomavirus Res. 2016, 2, 70-77. [CrossRef]
98. Zhan, L.; Rosenberg, A.; Bergami, K.C.; Yu, M.; Xuan, Z.; Jaffe, A.B.; Allred, C.; Muthuswamy, S.K. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 2008, 135, 865-878. [CrossRef] [PubMed]
99. Liu, Y.; Henry, G.D.; Hegde, R.S.; Baleja, J.D. Solution structure of the hDlg/SAP97 PDZ2 domain and its mechanism of interaction with HPV-18 papillomavirus E6 protein. Biochemistry 2007, 46, 10864-10874. [CrossRef] [PubMed]
100. Zhang, Y.; Dasgupta, J.; Ma, R.Z.; Banks, L.; Thomas, M.; Chen, X.S. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: Mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein. J. Virol. 2007, 81, 3618-3626. [CrossRef] [PubMed]
101. Tomaić, V.; Gardiol, D.; Massimi, P.; Ozbun, M.; Myers, M.; Banks, L. Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators. Oncogene 2009, 28, 1-8. [CrossRef] [PubMed]
102. Boon, S.S.; Banks, L. High-risk human papillomavirus E6 oncoproteins interact with 14-3-3ζ in a PDZ binding motif-dependent manner. J. Virol. 2013, 87, 1586-1595. [CrossRef] [PubMed]
103. Muslin, A.J.; Tanner, J.W.; Allen, P.M.; Shaw, A.S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996, 84, 889-897. [CrossRef]
104. Boon, S.S.; Tomaić, V.; Thomas, M.; Roberts, S.; Banks, L. Cancer-causing human papillomavirus E6 proteins display major differences in the phospho-regulation of their PDZ interactions. J. Virol. 2015, 89, 1579-1586. [CrossRef] [PubMed]
105. McIntyre, M.C.; Frattini, M.G.; Grossman, S.R.; Laimins, L.A. Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J. Virol. 1993, 67, 3142-3150. [PubMed]
106. Rawls, J.A.; Pusztai, R.; Green, M. Chemical synthesis of human papillomavirus type 16 E7 oncoprotein: Autonomous protein domains for induction of cellular DNA synthesis and for trans activation. J. Virol. 1990, 64, 6121-6129. [PubMed]
107. Patrick, D.R.; Oliff, A.; Heimbrook, D.C. Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J. Biol. Chem. 1994, 269, 6842-6850. [PubMed]
108. Oh, K.J.; Kalinina, A.;Wang, J.; Nakayama, K.; Nakayama, K.I.; Bagchi, S. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J. Virol. 2004, 78, 5338-5346. [CrossRef] [PubMed]
109. Firzlaff, J.M.; Galloway, D.A.; Eisenman, R.N.; Lüscher, B. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol. 1989, 1, 44-53. [PubMed]
110. Barbosa, M.S.; Edmond, C.; Fisher, C.; Schiller, J.T.; Lowy, D.R.; Vousden, K.H. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 1990, 9, 153-160. [PubMed]
111. Massimi, P.; Banks, L. Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle. Virology 2000, 276, 388-394. [CrossRef] [PubMed]
112. Banks, L.; Edmonds, C.; Vousden, K.H. Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene 1990, 5, 1383-1389. [PubMed]
113. Brokaw, J.L.; Yee, C.L.; Münger, K. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein. Virology 1994, 205, 603-607. [CrossRef] [PubMed]
114. Demers, G.W.; Espling, E.; Harry, J.B.; Etscheid, B.G.; Galloway, D.A. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J. Virol. 1996, 70, 6862-6869. [PubMed]
115. Huh, K.W.; DeMasi, J.; Ogawa, H.; Nakatani, Y.; Howley, P.M.; Münger, K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc. Natl. Acad. Sci. USA 2005, 102, 11492-11497. [CrossRef] [PubMed]
116. Huang, S.M.; McCance, D.J. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J. Virol. 2002, 76, 8710-8721. [CrossRef] [PubMed]
117. Nakatani, Y.; Konishi, H.; Vassilev, A.; Kurooka, H.; Ishiguro, K.; Sawada, J.; Ikura, T.; Korsmeyer, S.J.; Qin, J.; Herlitz, A.M. p600, a unique protein required for membrane morphogenesis and cell survival. Proc. Natl. Acad. Sci. USA 2005, 102, 15093-15098. [CrossRef] [PubMed]
118. DeMasi, J.; Huh, K.W.; Nakatani, Y.; Münger, K.; Howley, P.M. Bovine papillomavirus E7 transformation function correlates with cellular p600 protein binding. Proc. Natl. Acad. Sci. USA 2005, 102, 11486-11491. [CrossRef] [PubMed]
119. White, E.A.; Kramer, R.E.; Tan, M.J.; Hayes, S.D.; Harper, J.W.; Howley, P.M. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J. Virol. 2012, 86, 13174-13186. [CrossRef] [PubMed]
120. Firzlaff, J.M.; Lüscher, B.; Eisenman, R.N. Negative charge at the casein kinase II phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16. Proc. Natl. Acad. Sci. USA 1991, 88, 5187-5191. [CrossRef] [PubMed]
121. Chien, W.M.; Parker, J.N.; Schmidt-Grimminger, D.C.; Broker, T.R.; Chow, L.T. Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting S-phase entry. Cell Growth Differ. 2000, 11, 425-435. [PubMed]
122. Dyson, N.; Howley, P.M.; Münger, K.; Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243, 934-937. [CrossRef] [PubMed]
123. Slansky, J.E.; Farnham, P.J. Introduction to the E2F family: Protein structure and gene regulation. Curr. Top. Microbiol. Immunol. 1996, 208, 1-30. [PubMed]
124. Imai, Y.; Matsushima, Y.; Sugimura, T.; Terada, M. Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. J. Virol. 1991, 65, 4966-4972. [PubMed]
125. Boyer, S.N.; Wazer, D.E.; Band, V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996, 56, 4620-4624. [PubMed]
126. Huh, K.; Zhou, X.; Hayakawa, H.; Cho, J.Y.; Libermann, T.A.; Jin, J.; Harper, J.W.; Munger, K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 2007, 81, 9737-9747. [CrossRef] [PubMed]
127. Morris, E.J.; Dyson, N.J. Retinoblastoma protein partners. Adv. Cancer Res. 2001, 82, 1-54. [PubMed]
128. Davies, R.; Hicks, R.; Crook, T.; Morris, J.; Vousden, K. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J. Virol. 1993, 67, 2521-2528. [PubMed]
129. Baus, F.; Gire, V.; Fisher, D.; Piette, J.; Dulić, V. Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J. 2003, 22, 3992-4002. [CrossRef] [PubMed]
130. Ginsberg, D.; Vairo, G.; Chittenden, T.; Xiao, Z.X.; Xu, G.; Wydner, K.L.; DeCaprio, J.A.; Lawrence, J.B.; Livingston, D.M. E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev. 1994, 8, 2665-2679. [CrossRef] [PubMed]
131. Hijmans, E.M.; Voorhoeve, P.M.; Beijersbergen, R.L.; van’t Veer, L.J.; Bernards, R. E2F-5, a new E2F family member that interacts with p130 in vivo. Mol. Cell. Biol. 1995, 15, 3082-3089. [CrossRef] [PubMed]
132. Trimarchi, J.M.; Fairchild, B.; Verona, R.; Moberg, K.; Andon, N.; Lees, J.A. E2F-6, a member of the E2F family that can behave as a transcriptional repressor. Proc. Natl. Acad. Sci. USA 1998, 95, 2850-2855. [CrossRef] [PubMed]
133. McLaughlin-Drubin, M.E.; Huh, K.W.; Münger, K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J. Virol. 2008, 82, 8695-8705. [CrossRef] [PubMed]
134. Helt, A.M.; Galloway, D.A. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 2001, 75, 6737-6747. [CrossRef] [PubMed]
135. Jones, D.L.; Thompson, D.A.; Münger, K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 1997, 239, 97-107. [CrossRef] [PubMed]
136. Westbrook, T.F.; Nguyen, D.X.; Thrash, B.R.; McCance, D.J. E7 abolishes raf-induced arrest via mislocalization of p21 (Cip1). Mol. Cell. Biol. 2002, 22, 7041-7052. [CrossRef] [PubMed]
137. Brehm, A.; Nielsen, S.J.; Miska, E.A.; McCance, D.J.; Reid, J.L.; Bannister, A.J.; Kouzarides, T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 1999, 18, 2449-2458. [CrossRef] [PubMed]
138. Zhang, B.; Laribee, R.N.; Klemsz, M.J.; Roman, A. Human papillomavirus type 16 E7 protein increases acetylation of histone H3 in human foreskin keratinocytes. Virology 2004, 329, 189-198. [CrossRef] [PubMed]
139. Massimi, P.; Pim, D.; Banks, L. Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J. Gen. Virol. 1997, 78, 2607-2613. [CrossRef] [PubMed]
140. Schilling, B.; De-Medina, T.; Syken, J.; Vidal, M.; Münger, K. A novel human DnaJ protein, hTid-1, a homolog of the Drosophila tumor suppressor protein Tid56, can interact with the human papillomavirus type 16 E7 oncoprotein. Virology 1998, 247, 74-85. [CrossRef] [PubMed]
141. Bornens, M. Centrosome composition and microtubule anchoring mechanisms. Curr. Opin. Cell Biol. 2002, 14, 25-34. [CrossRef]
142. Sluder, G.; Nordberg, J.J. The good, the bad and the ugly: The practical consequences of centrosome amplification. Curr. Opin. Cell Biol. 2004, 16, 49-54. [CrossRef] [PubMed]
143. Nigg, E.A. Centrosome aberrations: Cause or consequence of cancer progression? Nat. Rev. Cancer 2002, 2, 815-825. [CrossRef] [PubMed]
144. Salisbury, J.L.; Whitehead, C.M.; Lingle, W.L.; Barrett, S.L. Centrosomes and cancer. Biol. Cell 1999, 91, 451-460. [CrossRef] [PubMed]
145. Tsou, M.F.; Stearns, T. Mechanism limiting centrosome duplication to once per cell cycle. Nature 2006, 442, 947-951. [CrossRef] [PubMed]
146. Lingle,W.L.; Lutz,W.H.; Ingle, J.N.; Maihle, N.J.; Salisbury, J.L. Centrosome hypertrophy in human breast tumors: Implications for genomic stability and cell polarity. Proc. Natl. Acad. Sci. USA 1998, 95, 2950-2955. [CrossRef] [PubMed]
147. Duensing, S. A tentative classification of centrosome abnormalities in cancer. Cell Biol. Int. 2005, 29, 352-359. [CrossRef] [PubMed]
148. Duensing, S.; Münger, K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002, 62, 7075-7082. [PubMed]
149. Duensing, S.; Duensing, A.; Crum, C.P.; Münger, K. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res. 2001, 61, 2356-2360. [PubMed]
150. Shinmura, K.; Bennett, R.A.; Tarapore, P.; Fukasawa, K. Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication. Oncogene 2007, 26, 2939-2944. [CrossRef] [PubMed]
151. Duensing, S.; Münger, K. Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members. J. Virol. 2003, 77, 12331-12335. [CrossRef] [PubMed]
152. Duensing, S.; Duensing, A.; Lee, D.C.; Edwards, K.M.; Piboonniyom, S.O.; Manuel, E.; Skaltsounis, L.; Meijer, L.; Münger, K. Cyclin-dependent kinase inhibitor indirubin-30-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 2004, 23, 8206-8215. [CrossRef] [PubMed]
153. Duensing, A.; Liu, Y.; Spardy, N.; Bartoli, K.; Tseng, M.; Kwon, J.A.; Teng, X.; Duensing, S. RNA polymerase II transcription is required for human papillomavirus type 16 E7- and hydroxyurea-induced centriole overduplication. Oncogene 2007, 26, 215-223. [CrossRef] [PubMed]
154. Egawa, N.; Egawa, K.; Griffin, H.; Doorbar, J. Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia. Viruses 2015, 7, 3863-3890. [CrossRef] [PubMed]
155. Darragh, T.M.; Winkler, B. Anal cancer and cervical cancer screening: Key differences. Cancer Cytopathol. 2011, 119, 5-19. [CrossRef] [PubMed]
156. Isaacson Wechsler, E.; Wang, Q.; Roberts, I.; Pagliarulo, E.; Jackson, D.; Untersperger, C.; Coleman, N.; Griffin, H.; Doorbar, J. Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression. J. Virol. 2012, 86, 6358-6364. [CrossRef] [PubMed]
157. Mirkovic, J.; Howitt, B.E.; Roncarati, P.; Demoulin, S.; Suarez-Carmona, M.; Hubert, P.; McKeon, F.D.; Xian,W.; Li, A.; Delvenne, P.; et al. Carcinogenic HPV infection in the cervical squamo-columnar junction. J. Pathol. 2015, 236, 265-271. [CrossRef] [PubMed]
158. Martens, J.E.; Smedts, F.M.; Ploeger, D.; Helmerhorst, T.J.; Ramaekers, F.C.; Arends, J.W.; Hopman, A.H. Distribution pattern and marker profile show two subpopulations of reserve cells in the endocervical canal. Int. J. Gynecol. Pathol. 2009, 28, 381-388. [CrossRef] [PubMed]
159. Herfs, M.; Vargas, S.O.; Yamamoto, Y.; Howitt, B.E.; Nucci, M.R.; Hornick, J.L.; McKeon, F.D.; Xian, W.; Crum, C.P. A novel blueprint for ‘top down’ differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia. J. Pathol. 2013, 229, 460-468. [CrossRef] [PubMed]
160. Mittal, S.; Banks, L. Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. Mutat. Res. Rev. Mutat. Res. 2016. [CrossRef]
161. Ottinger, M.; Smith, J.A.; Schweiger, M.R.; Robbins, D.; Powell, M.L.; You, J.; Howley, P.M. Cell-type specific transcriptional activities among different papillomavirus long control regions and their regulation by E2. Virology 2009, 395, 161-171. [CrossRef] [PubMed]
162. Dok, R.; Nuyts, S. HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers 2016. [CrossRef] [PubMed]
163. Hübbers, C.U.; Akgül, B. HPV and cancer of the oral cavity. Virulence 2015, 6, 244-248. [CrossRef] [PubMed]
164. Mirghani, H.; Amen, F.; Moreau, F.; Lacau St Guily, J. Do high-risk human papillomaviruses cause oral cavity squamous cell carcinoma? Oral Oncol. 2015, 51, 229-236. [CrossRef] [PubMed]
165. Westra, W.H. The morphologic profile of HPV-related head and neck squamous carcinoma: Implications for diagnosis, prognosis, and clinical management. Head Neck Pathol. 2012, 6, S48-S54. [CrossRef] [PubMed]
166. St Guily, J.L.; Clavel, C.; Okaïs, C.; Prétet, J.L.; Beby-Defaux, A.; Agius, G.; Birembaut, P.; Jacquard, A.C.; Léocmach, Y.; Soubeyrand, B.; et al. Human papillomavirus genotype distribution in tonsil cancers. Head Neck Oncol. 2011. [CrossRef] [PubMed]
167. Adams, A.K.; Wise-Draper, T.M.; Wells, S.I. Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers 2014, 6, 1793-1820. [CrossRef] [PubMed]
168. Chai, R.C.; Lambie, D.; Verma, M.; Punyadeera, C. Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med. 2015, 4, 596-607. [CrossRef] [PubMed]
169. Kreimer, A.R.; Johansson, M.; Waterboer, T.; Kaaks, R.; Chang-Claude, J.; Drogen, D.; Tjønneland, A.; Overvad, K.; Quirós, J.R.; González, C.A.; et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J. Clin. Oncol. 2013, 31, 2708-2715. [CrossRef] [PubMed]
170. Wallace, N.A.; Galloway, D.A. Novel Functions of the Human Papillomavirus E6 Oncoproteins. Annu. Rev. Virol. 2015, 2, 403-423. [CrossRef] [PubMed]
171. Cornet, I.; Bouvard, V.; Campo, M.S.; Thomas, M.; Banks, L.; Gissmann, L.; Lamartine, J.; Sylla, B.S.; Accardi, R.; Tommasino, M. Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J. Virol. 2012, 86, 2366-2370. [CrossRef] [PubMed]
172. Thomas, M.; Tomaić, V.; Pim, D.; Myers, M.P.; Tommasino, M.; Banks, L. Interactions between E6AP and E6 proteins from alpha and beta HPV types. Virology 2013, 435, 357-362. [CrossRef] [PubMed]
173. Brimer, N.; Lyons, C.;Wallberg, A.E.; Vande Pol, S.B. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling. Oncogene 2012, 31, 4639-4646. [CrossRef] [PubMed]
174. Meyers, J.M.; Spangle, J.M.; Munger, K. The human papillomavirus type 8 E6 protein interferes with NOTCH activation during keratinocyte differentiation. J. Virol. 2013, 87, 4762-4767. [CrossRef] [PubMed]
175. Lowell, S.; Jones, P.; Le Roux, I.; Dunne, J.; Watt, F.M. Stimulation of human epidermal differentiation by delta-notch signalling at the boundaries of stem-cell clusters. Curr. Biol. 2000, 10, 491-500. [CrossRef]
176. Rangarajan, A.; Talora, C.; Okuyama, R.; Nicolas, M.; Mammucari, C.; Oh, H.; Aster, J.C.; Krishna, S.; Metzger, D.; Chambon, P.; et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001, 20, 3427-3436. [CrossRef] [PubMed]
177. Muench, P.; Probst, S.; Schuetz, J.; Leiprecht, N.; Busch, M.; Wesselborg, S.; Stubenrauch, F.; Iftner, T. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Res. 2010, 70, 6913-6924. [CrossRef] [PubMed]
178. Muschik, D.; Braspenning-Wesch, I.; Stockfleth, E.; Rösl, F.; Hofmann, T.G.; Nindl, I. Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PLoS ONE 2011, 6, e27655. [CrossRef] [PubMed]
179. Bedard, K.M.; Underbrink, M.P.; Howie, H.L.; Galloway, D.A. The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes. J. Virol. 2008, 82, 3894-3902. [CrossRef] [PubMed]
180. Caldeira, S.; Zehbe, I.; Accardi, R.; Malanchi, I.; Dong, W.; Giarrè, M.; de Villiers, E.M.; Filotico, R.; Boukamp, P.; Tommasino, M. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J. Virol. 2003, 77, 2195-2206. [CrossRef] [PubMed]
181. Gabet, A.S.; Accardi, R.; Bellopede, A.; Popp, S.; Boukamp, P.; Sylla, B.S.; Londoño-Vallejo, J.A.; Tommasino, M. Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38. FASEB J. 2008, 22, 622-632. [CrossRef] [PubMed]
182. Holloway, A.; Simmonds, M.; Azad, A.; Fox, J.L.; Storey, A. Resistance to UV-induced apoptosis by β-HPV5 E6 involves targeting of activated BAK for proteolysis by recruitment of the HERC1 ubiquitin ligase. Int. J. Cancer 2015, 136, 2831-2843. [CrossRef] [PubMed]
183. Underbrink, M.P.; Howie, H.L.; Bedard, K.M.; Koop, J.I.; Galloway, D.A. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J. Virol. 2008, 82, 10408-10417. [CrossRef] [PubMed]
184. Barbosa, M.S.; Vass,W.C.; Lowy, D.R.; Schiller, J.T. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J. Virol. 1991, 65, 292-298. [PubMed]
185. Münger, K.; Werness, B.A.; Dyson, N.; Phelps, W.C.; Harlow, E.; Howley, P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989, 8, 4099-4105. [PubMed]
186. Accardi, R.; Dong,W.; Smet, A.; Cui, R.; Hautefeuille, A.; Gabet, A.S.; Sylla, B.S.; Gissmann, L.; Hainaut, P.; Tommasino, M. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep. 2006, 7, 334-340. [CrossRef] [PubMed]
187. Accardi, R.; Scalise, M.; Gheit, T.; Hussain, I.; Yue, J.; Carreira, C.; Collino, A.; Indiveri, C.; Gissmann, L.; Sylla, B.S.; et al. IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DeltaNp73alpha phosphorylation and stabilization. Mol. Cell. Biol. 2011, 31, 2210-2226. [CrossRef] [PubMed]
188. Saidj, D.; Cros, M.P.; Hernandez-Vargas, H.; Guarino, F.; Sylla, B.S.; Tommasino, M.; Accardi, R. Oncoprotein E7 from beta human papillomavirus 38 induces formation of an inhibitory complex for a subset of p53-regulated promoters. J. Virol. 2013, 87, 12139-12150. [CrossRef] [PubMed]
189. Tommasino, M. The human papillomavirus family and its role in carcinogenesis. Semin. Cancer Biol. 2014, 26, 13-21. [CrossRef] [PubMed]
190. Schaper, I.D.; Marcuzzi, G.P.; Weissenborn, S.J.; Kasper, H.U.; Dries, V.; Smyth, N.; Fuchs, P.; Pfister, H. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res. 2005, 65, 1394-1400. [CrossRef] [PubMed]
191. Viarisio, D.; Mueller-Decker, K.; Kloz, U.; Aengeneyndt, B.; Kopp-Schneider, A.; Gröne, H.J.; Gheit, T.; Flechtenmacher, C.; Gissmann, L.; Tommasino, M. E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog. 2011, 7, e1002125. [CrossRef] [PubMed]
192. Cotsarelis, G.; Sun, T.T.; Lavker, R.M. Label-retaining cells reside in the bulge area of pilosebaceous unit: Implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 1990, 61, 1329-1337. [CrossRef]
193. Cotsarelis, G. Epithelial stem cells: A folliculocentric view. J. Investig. Dermatol. 2006, 126, 1459-1468. [CrossRef] [PubMed]
194. Ghazizadeh, S.; Taichman, L.B. Organization of stem cells and their progeny in human epidermis. J. Investig. Dermatol. 2005, 124, 367-372. [CrossRef] [PubMed]